PDF(Pubmed)
Abstract：
Purpose: To investigate the associations between fluid accumulation at different levels in the retina and visual outcome in polypoidal choroidal vasculopathy (PCV). Design: A retrospective observational study. Institutional setting. Study Population: A total of 91 eyes from 91 patients of PCV were included, with 65 receiving intravitreal aflibercept monotherapy and 26 receiving combined intravitreal ranibizumab and photodynamic therapy (PDT). Observation Procedures: Best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) examination results were recorded at baseline and 3, 6, and 12 months after treatment. Main Outcome Measures: The correlations between visual outcomes and fluid biomarkers including intraretinal fluid (IRF), subretinal fluid (SRF), serous pigment epithelium detachment (PED), and hemorrhage at fovea were analyzed. Results: No differences in treatment outcomes were noted between patients receiving aflibercept and those receiving combined ranibizumab and PDT. IRF and hemorrhage at baseline predicted poorer vision at 3, 6, and 12 months. The presence of IRF was associated with poorer vision at 6 months and 12 months (p < 0.05 for all). The presence of SRF or PED was not associated with better vision at any time point. No differences in the correlations between fluid markers and visual outcomes were noted between thin and thick subfoveal choroidal thickness groups. Conclusions: For PCV, IRF and hemorrhage at baseline served as surrogates for poor visual prognosis after treatment, and IRF was a biomarker for poor vision during the treatment course. No fluid markers predicted good visual prognosis or had a positive impact on vision at any time point.
摘要：
目的：探讨息肉状脉络膜血管病变（PCV）视网膜中不同程度的液体积聚与视觉结局之间的关系。设计：回顾性观察性研究。机构设置。研究人群：共纳入91例PCV患者的91只眼，其中65人接受玻璃体内阿柏西普单药治疗，26人接受玻璃体内雷珠单抗和光动力疗法（PDT）联合治疗。观察程序：记录基线和治疗后3、6、12个月的最佳矫正视力（BCVA）和光学相干断层扫描（OCT）检查结果。主要结果指标：视觉结果与液体生物标志物之间的相关性，包括视网膜内液体（IRF），视网膜下液（SRF），浆液性色素上皮脱离（PED），并对中央凹出血进行分析。结果：接受阿柏西普治疗的患者与接受雷珠单抗和PDT联合治疗的患者之间的治疗结果没有差异。基线时的IRF和出血预测3、6和12个月时视力较差。IRF的存在与6个月和12个月时视力较差相关（均p<0.05）。SRF或PED的存在在任何时间点都与更好的视力无关。在薄和厚的中央凹下脉络膜厚度组之间，液体标志物与视觉结果之间的相关性没有差异。结论：对于PCV，IRF和基线出血作为治疗后视力预后不良的替代因素，IRF是治疗过程中视力不良的生物标志物。在任何时间点，没有液体标记物预测良好的视力预后或对视力产生积极影响。
